Supply Chain

Regardless of how Britain leaves the European Union, the global pharma industry must always lobby for positive change.

No-deal Brexit poses unique challenges for the development and advanced therapy sectors, not least tight timelines and a limited ability to stockpile.

Serialization will certainly help in the battle against counterfeiters, but there are other steps that manufacturers can take.

Here we discuss the problems of handling living, breathing cells in transit...

Single-source chromatography resin leads to requirements for supply security.

Brexit: As UK politicians debate the merits of the Prime Minister’s Withdrawal Agreement, we debate its potential impact for pharma...

Oscars of science, drug shortage reporting requirements, and a new gene therapy... What’s new for pharma in business?

Where is this variability come from? It's time for Gene and Eva to investigate!